Drug intelligence / Profile preview

anti-FSTL1 antibody

Development stage: Preclinical
Lead developer: Pharma Foods International
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous, Subcutaneous, Intramuscular, Intraperitoneal, Topical, Transdermal, Parenteral

Overview

Pharma Foods International's anti-FSTL1 antibody is a monoclonal antibody developed using the company's proprietary ALAgene® chicken-derived antibody technology. It targets Follistatin-like 1 (FSTL1), a secreted glycoprotein that is often upregulated in various cancers and is associated with epithelial-mesenchymal transition (EMT), tumor invasion, and metastasis. By neutralizing FSTL1, the antibody aims to inhibit tumor growth and progression. The program is currently in the preclinical stage for the treatment of malignant tumors.

Other names: 抗FSTL1抗体

Targets

FSTL1 (Follistatin-like protein 1)

Beyond the preview

Go deeper on anti-FSTL1 antibody.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on anti-FSTL1 antibody.

Explore the full profile